Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05176483
Title	Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors (STELLAR-002)
Acronym	STELLAR-002
Recruitment	Recruiting
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	Exelixis
Indications	bladder urothelial carcinoma renal pelvis transitional cell carcinoma papillary renal cell carcinoma renal cell carcinoma urethra transitional cell carcinoma prostate adenocarcinoma sarcomatoid renal cell carcinoma ureter transitional cell carcinoma Advanced Solid Tumor
Therapies	Nivolumab + NKTR-214 XL092 Nivolumab + NKTR-214 + XL092 Ipilimumab + Nivolumab + XL092 Nivolumab + XL092 Ipilimumab + Nivolumab
Age Groups:	adult \| senior
Covered Countries	USA \| NZL \| ITA \| GBR \| FRA \| ESP \| DEU \| BEL \| AUT \| AUS